Aquestive Therapeutics, Inc. (AQST)
Market Cap | 220.31M |
Revenue (ttm) | 51.50M |
Net Income (ttm) | -28.77M |
Shares Out | 91.04M |
EPS (ttm) | -0.43 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 688,535 |
Open | 2.380 |
Previous Close | 2.450 |
Day's Range | 2.360 - 2.440 |
52-Week Range | 1.251 - 6.230 |
Beta | 2.80 |
Analysts | Strong Buy |
Price Target | 8.71 (+259.92%) |
Earnings Date | Aug 5, 2024 |
About AQST
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of... [Read more]
Full Company ProfileFinancial Performance
In 2023, AQST's revenue was $50.58 million, an increase of 6.09% compared to the previous year's $47.68 million. Losses were -$7.87 million, -85.54% less than in 2022.
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for AQST stock is "Strong Buy." The 12-month stock price forecast is $8.71, which is an increase of 259.92% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/b/t/press20-2499555.jpg)
Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism
WARREN, N.J., June 27, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement...
![](https://cdn.snapi.dev/images/v1/l/e/press12-2458770.jpg)
Aquestive Therapeutics Announces Executive Appointments and Builds Commercial Capabilities
WARREN, N.J., June 03, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement...
![](https://cdn.snapi.dev/images/v1/f/k/press8-2420637.jpg)
Aquestive Therapeutics to Participate in The Citizens JMP Life Sciences Conference
WARREN, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through inno...
![](https://cdn.snapi.dev/images/v1/x/b/press9-2416329.jpg)
Aquestive Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
WARREN, N.J., May 07, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innov...
![](https://cdn.snapi.dev/images/v1/o/e/conf5-2369894.jpg)
Aquestive Therapeutics to Present Crossover Study Data for Libervant™ (diazepam) Buccal Film at 76th Annual Meeting of the American Academy of Neurology
WARREN, N.J., April 12, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to bring meaningful improvemen...
![](https://cdn.snapi.dev/images/v1/q/j/press10-2339540.jpg)
Aquestive Therapeutics Announces Closing of Underwritten Public Offering of Common Stock
WARREN, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvemen...
![](https://cdn.snapi.dev/images/v1/f/h/press10-2332270.jpg)
Aquestive Therapeutics Announces Pricing of $75 Million Underwritten Public Offering of Common Stock
WARREN, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvemen...
![](https://cdn.snapi.dev/images/v1/d/v/press8-2331779.jpg)
Aquestive Therapeutics Announces Proposed Public Offering of Common Stock
WARREN, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (Nasdaq: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to bring meaningful improvemen...
![](https://cdn.snapi.dev/images/v1/u/w/press8-2325512.jpg)
Aquestive Therapeutics Announces Pivotal Study for Anaphylm™ (epinephrine) Sublingual Film Successfully Meets Primary and Secondary Endpoints and Provides Clinical Development Update Following FDA Meeting
WARREN, N.J., March 14, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through in...
![](https://cdn.snapi.dev/images/v1/e/y/press5-2309754.jpg)
Aquestive Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
WARREN, N.J., March 05, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through inn...
![](https://cdn.snapi.dev/images/v1/n/i/conf16-2285699.jpg)
Aquestive Therapeutics to Report Fourth Quarter 2023 Financial Results and Recent Business Highlights on March 5 and Host Conference Call on March 6 at 8:00 a.m. ET
WARREN, N.J., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to bring meaningful improvement...
![](https://cdn.snapi.dev/images/v1/b/k/conf10-2277864.jpg)
Aquestive Therapeutics to Present Anaphylm™ (epinephrine) Sublingual Film Pharmacokinetic and Pharmacodynamic Data at the 2024 AAAAI Annual Meeting
WARREN, N.J., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to bring meaningful improvement...
![](https://cdn.snapi.dev/images/v1/c/d/press11-2250492.jpg)
Aquestive Therapeutics to Participate in Oppenheimer 34th Annual Healthcare Conference
WARREN, N.J., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through inn...
![](https://cdn.snapi.dev/images/v1/l/h/press9-2183503.jpg)
Aquestive Therapeutics Doses First Patient in Phase 3 Pivotal Clinical Study Evaluating Pharmacokinetics and Pharmacodynamics of Anaphylm™ (epinephrine) Sublingual Film
WARREN, N.J., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to bring meaningful improvement...
![](https://cdn.snapi.dev/images/v1/b/y/conf15-2152042.jpg)
Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies for Anaphylm™ at American College of Allergy Asthma and Immunology (ACAAI) Annual Meeting
WARREN, N.J., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to bring meaningful improvement...
![](https://cdn.snapi.dev/images/v1/p/q/press17-2142696.jpg)
Aquestive Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
WARREN, N.J., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through inno...
![](https://cdn.snapi.dev/images/v1/n/t/press17-2135843.jpg)
Aquestive Therapeutics Completes $45 Million Debt Refinancing
WARREN, N.J., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through inno...
![](https://cdn.snapi.dev/images/v1/y/e/press2-2094813.jpg)
Aquestive Therapeutics Provides Business Update
WARREN, N.J., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and ...
![](https://cdn.snapi.dev/images/v1/e/4/press19-2070950.jpg)
Aquestive Therapeutics Reaffirms Timeline and Pathway for Anaphylm™ (epinephrine) Sublingual Film
WARREN, N.J., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and...
![](https://cdn.snapi.dev/images/v1/t/x/conf11-2033919.jpg)
Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences
WARREN, N.J., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to solve patients' problems wit...
![](https://cdn.snapi.dev/images/v1/d/g/press17-2010444.jpg)
Aquestive Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
WARREN, N.J., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and ...
![](https://cdn.snapi.dev/images/v1/7/j/press2-2001153.jpg)
Aquestive Therapeutics to Participate in 2023 Wedbush PacGrow Healthcare Conference
WARREN, N.J., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to solve patients' problems wit...
![](https://cdn.snapi.dev/images/v1/c/f/conf5-1987490.jpg)
Aquestive Therapeutics to Report Second Quarter 2023 Financial Results and Recent Business Highlights on August 7 and Host Conference Call on August 8 at 8:00 a.m. ET
WARREN, N.J., July 25, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to solve patients' problems wi...
![](https://cdn.snapi.dev/images/v1/o/y/conf20-1986089.jpg)
Aquestive Therapeutics to Present Positive Topline Data from Pharmacokinetic and Pharmacodynamic Studies of Anaphylm ™ (epinephrine) Sublingual Film at Aspen Allergy Conference
WARREN, N.J., July 25, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to solve patients' problems wit...
![](https://cdn.snapi.dev/images/v1/m/q/press6-1953202.jpg)
Aquestive Therapeutics Provides Business Update and Announces Chief Medical Officer Appointment
WARREN, N.J., June 29, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to solve patients' problems wit...